Loading...

NanoVibronix

Nasdaq:NAOV
Snowflake Description

Limited growth with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NAOV
Nasdaq
$23M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. The last earnings update was 57 days ago. More info.


Add to Portfolio Compare Print
  • NanoVibronix has significant price volatility in the past 3 months.
NAOV Share Price and Events
7 Day Returns
8.4%
NasdaqCM:NAOV
-0.5%
US Medical Equipment
0.8%
US Market
1 Year Returns
-24.9%
NasdaqCM:NAOV
14.6%
US Medical Equipment
4.8%
US Market
NAOV Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
NanoVibronix (NAOV) 8.4% -11% -11.7% -24.9% -37.6% -
US Medical Equipment -0.5% 3.1% 6.4% 14.6% 62% 103.5%
US Market 0.8% 4.3% 2.8% 4.8% 37.9% 43.5%
1 Year Return vs Industry and Market
  • NAOV underperformed the Medical Equipment industry which returned 14.6% over the past year.
  • NAOV underperformed the Market in United States of America which returned 4.8% over the past year.
Price Volatility
NAOV
Industry
5yr Volatility vs Market

Value

 Is NanoVibronix undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether NanoVibronix is trading at an attractive price based on the cash flow it is expected to produce in the future. But as NanoVibronix has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for NanoVibronix. This is due to cash flow or dividend data being unavailable. The share price is $3.3807.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for NanoVibronix's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are NanoVibronix's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:NAOV PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.89
NasdaqCM:NAOV Share Price ** NasdaqCM (2019-07-15) in USD $3.38
United States of America Medical Equipment Industry PE Ratio Median Figure of 64 Publicly-Listed Medical Equipment Companies 40.99x
United States of America Market PE Ratio Median Figure of 3,084 Publicly-Listed Companies 18.01x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of NanoVibronix.

NasdaqCM:NAOV PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:NAOV Share Price ÷ EPS (both in USD)

= 3.38 ÷ -0.89

-3.81x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NanoVibronix is loss making, we can't compare its value to the US Medical Equipment industry average.
  • NanoVibronix is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does NanoVibronix's expected growth come at a high price?
Raw Data
NasdaqCM:NAOV PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.81x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-4%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 55 Publicly-Listed Medical Equipment Companies 2.32x
United States of America Market PEG Ratio Median Figure of 2,124 Publicly-Listed Companies 1.59x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for NanoVibronix, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on NanoVibronix's assets?
Raw Data
NasdaqCM:NAOV PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $-0.07
NasdaqCM:NAOV Share Price * NasdaqCM (2019-07-15) in USD $3.38
United States of America Medical Equipment Industry PB Ratio Median Figure of 183 Publicly-Listed Medical Equipment Companies 4.34x
United States of America Market PB Ratio Median Figure of 5,240 Publicly-Listed Companies 1.81x
NasdaqCM:NAOV PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:NAOV Share Price ÷ Book Value per Share (both in USD)

= 3.38 ÷ -0.07

-49.09x

* Primary Listing of NanoVibronix.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NanoVibronix has negative assets, we can't compare the value of its assets to the US Medical Equipment industry average.

Next steps:

  1. Take a look at our analysis of NAOV’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through NanoVibronix's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Medical Equipment industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess NanoVibronix's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. NanoVibronix has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is NanoVibronix expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is NanoVibronix expected to grow at an attractive rate?
  • Unable to compare NanoVibronix's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare NanoVibronix's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • NanoVibronix's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:NAOV Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:NAOV Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -4%
NasdaqCM:NAOV Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 91.7%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.9%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.1%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:NAOV Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:NAOV Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 5 -7 1
2020-12-31 1 -7 1
2019-12-31 0 -7 1
NasdaqCM:NAOV Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 0 -4 -6
2018-12-31 0 -4 -4
2018-09-30 0 -3 -4
2018-06-30 0 -3 -4
2018-03-31 0 -3 -6
2017-12-31 0 -2 -6
2017-09-30 0 -2 -5
2017-06-30 0 -2 -4
2017-03-31 0 -2 -3
2016-12-31 0 -2 -3
2016-09-30 0 -1 -2
2016-06-30 0 -1 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • NanoVibronix is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • NanoVibronix's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:NAOV Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from NanoVibronix Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:NAOV Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -0.72 -0.72 -0.72 1.00
2020-12-31 -0.83 -0.83 -0.83 1.00
2019-12-31 -0.96 -0.96 -0.96 1.00
NasdaqCM:NAOV Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.89
2018-12-31 -0.64
2018-09-30 -0.58
2018-06-30 -0.62
2018-03-31 -0.89
2017-12-31 -0.90
2017-09-30 -1.15
2017-06-30 -0.94
2017-03-31 -0.70
2016-12-31 -0.62
2016-09-30 -0.54
2016-06-30 -0.64

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if NanoVibronix will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess NanoVibronix's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
NanoVibronix has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has NanoVibronix performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare NanoVibronix's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • NanoVibronix does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare NanoVibronix's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare NanoVibronix's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
NanoVibronix's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from NanoVibronix Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:NAOV Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 0.32 -6.04 5.26 0.63
2018-12-31 0.32 -4.15 3.85 0.61
2018-09-30 0.33 -3.76 3.51 0.63
2018-06-30 0.34 -4.01 2.79 0.67
2018-03-31 0.26 -5.72 2.57 0.68
2017-12-31 0.24 -5.81 2.55 0.69
2017-09-30 0.22 -5.29 2.46 0.61
2017-06-30 0.21 -4.29 2.38 0.61
2017-03-31 0.22 -3.21 2.17 0.62
2016-12-31 0.23 -2.83 1.87 0.58
2016-09-30 0.22 -2.49 1.51 0.55
2016-06-30 0.20 -2.93 1.38 0.48
2016-03-31 0.18 -2.75 1.28 0.42
2015-12-31 0.15 -2.88 1.12 0.40
2015-09-30 0.16 -2.90 0.91 0.45
2015-06-30 0.15 -2.63 1.04 0.46
2015-03-31 0.17 -2.77 1.03 0.44
2014-12-31 0.20 -2.65 0.89 0.43
2014-09-30 0.20 -2.42 0.78 0.40
2014-06-30 0.18 -2.01 0.49 0.37
2014-03-31 0.24 -1.69 0.35 0.38
2013-12-31 0.21 -1.99 0.61 0.62
2013-09-30 0.22 -1.64 0.63 0.55
2013-06-30 0.26 -1.69 0.58 0.71
2013-03-31 0.17 -1.75 0.58 0.76
2012-12-31 0.17 -1.28 0.32 0.57

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if NanoVibronix has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if NanoVibronix has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if NanoVibronix improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess NanoVibronix's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
NanoVibronix has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is NanoVibronix's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up NanoVibronix's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • NanoVibronix's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • NanoVibronix's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of NanoVibronix's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • NanoVibronix has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from NanoVibronix Company Filings, last reported 3 months ago.

NasdaqCM:NAOV Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 -0.47 0.00 0.18
2018-12-31 0.46 0.00 0.90
2018-09-30 1.39 0.00 1.73
2018-06-30 2.22 0.00 2.52
2018-03-31 2.95 0.00 3.49
2017-12-31 3.63 0.00 4.36
2017-09-30 -4.29 1.39 0.08
2017-06-30 -3.05 0.71 0.22
2017-03-31 -2.80 0.13 0.05
2016-12-31 -2.50 0.00 0.11
2016-09-30 -1.60 0.00 0.53
2016-06-30 -1.16 0.00 0.80
2016-03-31 -0.61 0.00 1.28
2015-12-31 -0.21 0.00 1.61
2015-09-30 0.51 0.00 1.99
2015-06-30 1.47 0.00 2.26
2015-03-31 0.23 1.50 2.80
2014-12-31 -5.62 4.62 0.09
2014-09-30 -4.92 4.43 0.04
2014-06-30
2014-03-31 -3.75 3.41 0.04
2013-12-31 -3.30 3.11 0.09
2013-09-30 -2.77 2.59 0.05
2013-06-30 -2.42 2.44 0.09
2013-03-31 -1.83 1.95 0.10
2012-12-31 -1.83 1.95 0.10
  • NanoVibronix has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if NanoVibronix's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • NanoVibronix has less than a year of cash runway based on current free cash flow.
  • NanoVibronix has less than a year of cash runway if free cash flow continues to grow at historical rates of 36.7% each year.
X
Financial health checks
We assess NanoVibronix's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. NanoVibronix has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is NanoVibronix's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from NanoVibronix dividends.
If you bought $2,000 of NanoVibronix shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate NanoVibronix's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate NanoVibronix's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:NAOV Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2018 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:NAOV Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as NanoVibronix has not reported any payouts.
  • Unable to verify if NanoVibronix's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of NanoVibronix's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as NanoVibronix has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess NanoVibronix's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can NanoVibronix afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. NanoVibronix has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of NanoVibronix's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Brian Murphy
COMPENSATION $590,897
AGE 62
TENURE AS CEO 2.8 years
CEO Bio

Mr. Brian M. Murphy has been the Chief Executive Officer of NanoVibronix Inc. since October 13, 2016. Mr. Murphy has over 25 years of sales, operations and general management experience in medical devices and medical technology fields. From 2012 to 2016, Mr. Murphy served as national director of commercial sales and national director of national accounts at MiMedx Group, Inc. (NASDAQ: MDXG), a biotechnology company developing and marketing regenerative biomaterial products and launched commercial sales and oversaw growth of the business. From 2010 to 2012, Mr. Murphy was the chief executive officer of O2 Insights, Inc. From 2008 to 2010, Mr. Murphy served as vice president of sales for ConvaTec, a global medical products and technologies company and led the negative pressure wound therapy business. From 1992 to 2008, Mr. Murphy served a total of 17 years at Kinetic Concepts, Inc. (now a subsidiary of Acelity L.P. Inc.) (KCI) in various positions overseeing sales, operations and general management. During his employment at KCI, Mr. Murphy led growth of the wound care division's business from generating $11 million to $550 million in annual revenues, as well as significant growth in the medical services and therapeutic surfaces businesses. Prior to working at KCI, Mr. Murphy served in sales and general manager positions at various companies in the medical device industry, including ATI Medical Equipment Corporation, Mountain Medical Equipment Inc. and Healthdyne Technologies Inc. He has been a Director of NanoVibronix Inc. since October 13, 2016. Mr. Murphy's qualifications to serve on the Board include his significant sales, operational and business insight from his prior management experience in the medical fields. Mr. Murphy holds a Bachelor of Arts degree in communications from Southern Illinois University.

CEO Compensation
  • Brian's compensation has increased whilst company is loss making.
  • Brian's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the NanoVibronix management team in years:

2.8
Average Tenure
63
Average Age
  • The tenure for the NanoVibronix management team is about average.
Management Team

Brian Murphy

TITLE
CEO & Director
COMPENSATION
$591K
AGE
62
TENURE
2.8 yrs

Steve Brown

TITLE
Consultant
COMPENSATION
$225K
AGE
63
TENURE
0.2 yrs

William Stern

TITLE
President
COMPENSATION
$232K
AGE
77
TENURE
2.8 yrs

Jay Cardwell

TITLE
Chief Financial Officer
AGE
58
TENURE
0.2 yrs

Amir Rippel

TITLE
Vice President of Marketing

Lindsey Harrison

TITLE
Vice President of Sales

Harold Jacob

TITLE
Chief Medical Officer & Director
COMPENSATION
$11K
AGE
65
TENURE
5.3 yrs
Board of Directors Tenure

Average tenure and age of the NanoVibronix board of directors in years:

4.3
Average Tenure
65.5
Average Age
  • The tenure for the NanoVibronix board of directors is about average.
Board of Directors

Chris Fashek

TITLE
Chairman of the Board
COMPENSATION
$150K
AGE
69
TENURE
2.8 yrs

Brian Murphy

TITLE
CEO & Director
COMPENSATION
$591K
AGE
62
TENURE
2.8 yrs

Harold Jacob

TITLE
Chief Medical Officer & Director
COMPENSATION
$11K
AGE
65
TENURE
15.8 yrs

Tom Mika

TITLE
Independent Director
AGE
66
TENURE
4.3 yrs

Mike Ferguson

TITLE
Independent Director
AGE
47
TENURE
4.3 yrs

Phil Hanno

TITLE
Member of Medical Advisory Board

Samuel Pinchas

TITLE
Member of Medical Advisory Board

Dennis Maki

TITLE
Member of Medical Advisory Board

Shalom Hirschman

TITLE
Member of Medical Advisory Board
AGE
83

Yechezkiel Caine

TITLE
Member of Medical Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess NanoVibronix's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. NanoVibronix has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Who Owns Most Of NanoVibronix Inc (NASDAQ:NAOV)?

In this article, I'm going to take a look at NanoVibronix Inc’s (NASDAQ:NAOV) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … The impact of a company's ownership structure affects both its short- and long-term performance. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment.

Simply Wall St -

When Will NanoVibronix Inc (NASDAQ:NAOV) Run Out Of Cash?

Check out our latest analysis for NanoVibronix What is cash burn? … My cash burn analysis suggests that NanoVibronix has a cash runway of 1.3 years, given its current level of cash holdings. … The cash burn analysis result indicates a cash constraint for the company, due to its high opex growth and its level of cash reserves.

Simply Wall St -

Should NanoVibronix Inc's (NASDAQ:NAOV) Recent Earnings Decline Worry You?

When NanoVibronix Inc (NASDAQ:NAOV) released its most recent earnings update (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance of its industry peers on average. … View our latest analysis for NanoVibronix Was NAOV's recent earnings decline worse than the long-term trend and the industry? … For the purpose of this commentary, I like to use data from the most recent 12 months, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data.

Simply Wall St -

Who Are The Major Shareholders Of NanoVibronix Inc (NASDAQ:NAOV)?

With this size of ownership, retail investors can collectively play a role in major company policies that affect shareholders returns, including executive remuneration and the appointment of directors. … Private Company Ownership Potential investors in NAOV should also look at another important group of investors: private companies, with a stake of 5.04%, who are primarily invested because of strategic and capital gain interests. … As a result, potential investors should further explore the company's business relations with these companies and find out if they can affect shareholder returns in the long-term.Next Steps: I suggest investors seek some degree of margin of safety due to high institutional ownership in NAOV, in particular due to the strong presence of active hedge fund investors.

Simply Wall St -

Before You Invest In NanoVibronix Inc (NASDAQ:NAOV), Consider This Factor

Check out our latest analysis for NanoVibronix What is cash burn? … The measure of how fast NanoVibronix goes through its cash reserves over time is called the cash burn rate. … My cash burn analysis suggests that, if NanoVibronix continues to spend its cash reserves at this current high rate, it’ll have to raise capital within the upcoming months, which may be a surprise to some shareholders.

Simply Wall St -

Does NanoVibronix Inc's (NASDAQ:NAOV) -78.3% EPS Decline Reflect A Long-Term Trend?

After reading NanoVibronix Inc's (NASDAQ:NAOV) most recent earnings announcement (30 September 2017), I found it useful to look back at how the company has performed in the past and compare this against the latest numbers. … View our latest analysis for NanoVibronix Commentary On NAOV's Past Performance I like to use data from the most recent 12 months, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records2

Simply Wall St -

NasdaqCM Healthcare Industry: A Deep Dive Into NanoVibronix Inc (NAOV)

Below, I will examine the sector growth prospects, and also determine whether NAOV is a laggard or leader relative to its healthcare sector peers. … If your initial investment thesis is around the growth prospects of NAOV, there are other healthcare equipment companies that have delivered higher growth, and perhaps trading at a discount to the industry average. … Although its growth has delivered lower growth relative to its healthcare equipment peers in the near term, the market may be pessimistic on the stock, leading to a potential undervaluation.

Simply Wall St -

What You Must Know About NanoVibronix Inc's (NAOV) Major Investors

See our latest analysis for NAOV NasdaqCM:NAOV Ownership Summary Nov 14th 17 Institutional Ownership Due to the big order sizes of institutional investors, a company's shares can experience large, one-sided momentum, driven by high volume of shares removed from, or injected into, the market. … Private Company Ownership Potential investors in NAOV should also look at another important group of investors: private companies, with a stake of 4.93%, who are primarily invested because of strategic and capital gain interests. … With a low level of institutional ownership, investors in NAOV need not worry about non-fundamental factors such as ownership structure causing large impact on stock prices.

Simply Wall St -

Company Info

Description

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products in the United States, Israel, Europe, India, and internationally through distributor agreements. NanoVibronix, Inc. was founded in 2003 and is based in Elmsford, New York.

Details
Name: NanoVibronix, Inc.
NAOV
Exchange: NasdaqCM
Founded: 2003
$23,152,081
6,848,310
Website: http://www.nanovibronix.com
Address: NanoVibronix, Inc.
525 Executive Boulevard,
Elmsford,
New York, 10523,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM NAOV Common Stock Nasdaq Capital Market US USD 29. Apr 2015
Number of employees
Current staff
Staff numbers
10
NanoVibronix employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/16 00:53
End of day share price update: 2019/07/15 00:00
Last estimates confirmation: 2019/06/03
Last earnings filing: 2019/05/20
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.